Three independent clinical trials investigated the effect of different CD19 targeting CAR T products in DLBCL and reported outcomes of patients with MYC overexpressing lymphomas as subgroups [173,174,175]. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.